Consensus statement on the use of clozapine during the COVID-19 pandemic

Consensus statement on the use of clozapine during the COVID-19 pandemic

J Psychiatry Neurosci 2020;45(4):45-4-200061 | PDF

Dan Siskind, MBBS, PhD; William G. Honer, MD; Scott Clark, MBBS, PhD; Christoph U. Correll, MD; Alkomiet Hasan,MD; Oliver Howes, MD, PhD; John M. Kane, MD; Deanna L. Kelly, PharmD; Robert Laitman, MD; Jimmy Lee, MBBS, MMed; James H. MacCabe, MD, PhD; Nick Myles, MD; Jimmi Nielsen, MD, PhD; Peter F. Schulte, MD, PhD; David Taylor, PhD; Helene Verdoux, MD, PhD; Amanda Wheeler, PhD; Oliver Freudenreich, MD


The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided.

Published online on April 3, 2020; subject to revision

Affiliations: From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind); the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles); the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer); the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane); the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane); the Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll); Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany (Correll); the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hassan); the Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK (Howes, MacCabe); the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes); the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes); the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly); the Bronx Westchester Medical Group, New York, NY, USA (Laitman); the North Region & Department of Psychosis, Institute of Mental Health, Singapore (Lee); the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee); the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen (Nielsen); the Mental Health Service Noord-Holland-Noord, Alkmaar, The Netherlands (Schulte); the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor); the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux); the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler); the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA (Freudenreich); and the Harvard Medical School, Boston, MA, USA (Freudenreich).

Competing interests: W. Honer has received consulting fees or sat on paid advisory boards for the Canadian Agency for Drugs and Technology in Health, AlphaSights, Guidepoint, In Silico, Translational Life Sciences, Otsuka, Lundbeck and Newron. S. Clark has recieved an investigator-initated grant, participated in an advisory and an educational board and recieved speakers fees from Lundbeck-Otsuka Australia and received an investigator-initiated grant from Janssen-Cilag Australia. He has received speakers fees from Servier Australia. C. Correll has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a data safety monitoring board for Lundbeck, Rovi, Supernus and Teva. He has received grant support from the Berlin Institute of health, Janssen, the National Institute of Mental Health, Patient Centered Outcomes Research Institute, Takeda and the Thrasher Foundation. He has received royalties from UpToDate and is a stock option holder of LB Pharma. A. Hasan has been on the advisory boards and has received speaker fees from Janssen, Lundbeck and Otsuka. O. Howes reports receiving speaker fees, participating on advisory boards, and/or receiving investigator-initiated funding from manufacturers of antipsychotics, including clozapine. J. Kane declares consulting fees/honoraria from Acadia, Alkermes, Allergan, Eli Lilly, Forum, Genentech, Dainippon Sumitomo, H. Lundbeck, Intracellular Therapies, Janssen Pharmaceutical, Jazz Pharma, Johnson & Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda and Teva, as well as grant support from Otsuka, Lundbeck and Janssen. He is also a shareholder in Vanguard Research Group and LB Pharmaceuticals, Inc. D. Kelly has served as a consultant for Lundbeck, HLS Therapeutics and Alkermes, and is a joint holder of a patent for analytical microdevices for mental health treatment monitoring (US9581536B2). J. MacCabe has received research grants from, and acted as an unpaid consultant to Lundbeck and Saladax Biomedical. D. Taylor has received research funding from Janssen and Sunovion and lecture payments form Janssen, Lundbeck, Otsuka and Recordati. O. Freudenreich has received a grant from Avanir for a clinical trial involving patients taking clozapine and royalties from UpToDate for the entry on clozapine. No other authors declared competing interests.

DOI: 10.1503/jpn.200061